Microtransplantation for treating recurrent ovarian cancer
Microtransplantation for Ovarian Cancer
This study is testing if a new treatment using stem cells from mismatched donors can help people with recurrent ovarian cancer feel better after standard chemotherapy and radiation.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | Female |
| Sponsor | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT05095558 on ClinicalTrials.gov |
What this trial studies
This study investigates the efficacy and safety of microtransplantation in patients with recurrent and advanced ovarian cancer. Eligible participants are assigned to either the experimental group, receiving peripheral blood hematopoietic stem cells from HLA mismatched donors after conventional chemotherapy and/or radiotherapy, or the control group, which receives only conventional treatments. The treatment plan is individualized based on the patient's medical history and tumor assessment, with evaluations conducted after each treatment cycle to determine efficacy and safety. Patients who do not show improvement after two cycles of chemotherapy will be withdrawn from the study.
Who should consider this trial
Good fit: Ideal candidates are women aged 18-80 with advanced or relapsed ovarian cancer who have suitable hematopoietic stem cell donors.
Not a fit: Patients without suitable donors or those who refuse donor cells may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a new treatment option that enhances the effectiveness of existing therapies for ovarian cancer.
How similar studies have performed: While the approach of microtransplantation is relatively novel in this context, similar studies in other cancers have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients are 18-80 years old, female，regardless of race; * Advanced / relapsed ovarian cancer confirmed by clinical or histopathological diagnosis; * More than two kinds of tumors are allowed; * Karnofsky score ≥ 60, ECoG physical status ≤ 2; * Sensitive to chemotherapy or radiotherapy; * There are measurable lesions; * There are suitable hematopoietic stem cell donors Exclusion Criteria: * have no suitable donor or donor refused * patient refused to accept donor cells
Where this trial is running
Beijing, Beijing
- The third medical center of PLA General Hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Study coordinator: Weiping Li
- Email: 15811031508@163.com
- Phone: +8615811031508
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.